Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics

This cross-sectional study evaluates the duration between application to US Food and Drug Administration (FDA) and approval for new drugs and biologics in the US from 2015 to 2022.